Peptides for Post-Concussion Syndrome — Evidence-Based Overview

How peptide Targets Peptides for Post-Concussion Syndrome

Post-concussion syndrome (PCS) refers to the constellation of symptoms that persist for weeks, months, or even years after a mild traumatic brain injury (concussion). Unlike moderate-to-severe TBI where structural damage is evident on imaging, concussions typically show no abnormalities on standard CT or MRI, yet patients experience debilitating headaches, cognitive fog, memory problems, difficulty concentrating, dizziness, fatigue, sleep disturbance, anxiety, depression, and light/noise sensitivity. The underlying pathophysiology involves persistent neuroinflammation driven by chronically activated microglia, diffuse axonal injury at the microstructural level, disrupted neurotransmitter balance (particularly glutamate/GABA imbalance), impaired cerebral blood flow autoregulation, mitochondrial dysfunction, and disrupted blood-brain barrier integrity. These processes create a self-sustaining cycle of neuroinflammation and neural dysfunction that standard clinical treatments address only symptomatically.

Cerebrolysin has the most clinical evidence among peptide-based interventions for brain injury, though most trials have focused on moderate-to-severe TBI and stroke rather than PCS specifically. Its mixture of neurotrophic peptides mimics the activity of BDNF, NGF, GDNF, and CNTF — providing broad neurotrophic support that addresses multiple aspects of PCS pathology. In clinical studies of TBI, cerebrolysin has improved cognitive outcomes including memory, attention, and processing speed — the same cognitive domains impaired in PCS. Its ability to promote synaptic plasticity, reduce excitotoxicity, and modulate neuroinflammation makes it one of the more rationally supported peptide interventions for post-concussive cognitive dysfunction. Semax (ACTH 4-10 analogue) upregulates endogenous BDNF and NGF production in the brain, providing neurotrophic support that may help restore disrupted neural circuits. Russian clinical experience includes use in mild TBI and cognitive rehabilitation, with reported improvements in cognitive function, though these studies generally do not meet rigorous Western trial standards. Semax also modulates inflammatory cytokine profiles in the brain, which is relevant to the persistent neuroinflammation that sustains PCS symptoms.

Selank (tuftsin analogue) addresses the psychiatric dimension of PCS — the anxiety, emotional dysregulation, and cognitive-emotional interference that often dominate the clinical picture. Selank modulates GABAergic neurotransmission, reduces anxiety-related behavior in preclinical models, and has nootropic properties that may support cognitive function. For PCS patients whose primary complaints are anxiety, emotional lability, and the cognitive impact of chronic stress and sleep disruption, selank's anxiolytic and cognitive-supportive properties are mechanistically relevant. Dihexa, the angiotensin IV analogue, has shown extraordinary potency in promoting synaptic connectivity through HGF/c-Met signaling in preclinical studies. Concussions disrupt synaptic connections at the microstructural level, and enhancing synaptic repair and plasticity is a theoretically sound approach to PCS recovery. However, dihexa's evidence base is extremely limited with few preclinical publications and no human data. BPC-157 has demonstrated neuroprotective effects in rodent TBI models, including modulation of neurotransmitter systems (dopamine, serotonin) that are disrupted after concussion. Its effects on the nitric oxide system and cerebral blood flow regulation may also be relevant, as impaired cerebrovascular autoregulation is a recognized contributor to PCS symptoms including exercise intolerance and headaches. The honest assessment is that PCS is an under-treated condition where current medicine relies on symptomatic management and time. Cerebrolysin has the most evidence, semax and selank have specific mechanistic relevance, and BPC-157 and dihexa have preclinical rationale but lack human PCS data.